HHS Plans New Deputy Commissioner Roles at FDA Focused on Technology and Drugs
The Department of Health and Human Services (HHS) is reportedly planning to create two new deputy commissioner roles within the Food and Drug Administration (FDA): one focused on technology, including health-related artificial intelligence, and another for drugs. These positions would report directly to Heidi Overton, Trump's nominee for FDA commissioner, who still requires Senate confirmation. The move appears aimed at increasing administrative influence over the agency amid recent controversies involving drug approvals and food safety issues like a cyclospora outbreak linked to iceberg lettuce. Potential candidates include Jared Seehafer, an industry veteran with experience in life sciences compliance software, for the technology role, while Kyle Diamantas is under consideration for returning as deputy commissioner for drugs or food. The FDA has faced heightened scrutiny over its recent decisions on drug approvals and regulatory approaches, including a controversial demand for additional clinical trials. The agency's evolving leadership structure comes at a time of significant public and industry attention.
Topics: appointments deputy commissioners FDA HHS